Publications by authors named "B H Sielaff"

Repulsive guidance molecule A (RGMa) is upregulated in neurodegenerative diseases. To assess RGMa levels in human serum and cerebrospinal fluid (CSF), a quantification method was developed and validated according to ICH M10 guideline. Sample preparation consisted of immunoprecipitation (IP, only for serum), digestion and purification followed by MS.

View Article and Find Full Text PDF

CTLA4-Ig/abatacept dampens activation of naive T cells by blocking costimulation via CD28. It is an approved drug for rheumatoid arthritis but failed to deliver efficacy in a number of other autoimmune diseases. One explanation is that activated T cells rely less on CD28 signaling and use alternate coreceptors for effector function.

View Article and Find Full Text PDF

Background: CD40 is a 48 kDa type I transmembrane protein that is constitutively expressed on hematopoietic cells such as dendritic cells, macrophages, and B cells. Engagement of CD40 by CD40L expressed on T cells results in the production of proinflammatory cytokines, induces T helper cell function, and promotes macrophage activation. The involvement of CD40 in chronic immune activation has resulted in CD40 being proposed as a therapeutic target for a range of chronic inflammatory diseases.

View Article and Find Full Text PDF

IL-36 cytokines are pro-inflammatory members of the IL-1 family that are upregulated in inflammatory disorders. Specifically, IL-36γ is highly expressed in active psoriatic lesions and can drive pro-inflammatory processes in 3D human skin equivalents supporting a role for this target in skin inflammation. Small molecule antagonists of interleukins have been historically challenging to generate.

View Article and Find Full Text PDF
Article Synopsis
  • IL-36 cytokines signal via the IL-36 receptor (IL-36R) and the accessory protein IL-1RAcP, forming complexes with agonists like IL-36α, IL-36β, and IL-36γ to activate the pathway.
  • Recent experiments demonstrated that IL-36R can interact with IL-1RAcP even without a ligand, but only strongly binds to IL-1RAcP in the presence of IL-36α.
  • The findings provide insight into how IL-36 pathway activation occurs through complex formation, and reveal that the IL-36Ra antagonist binds more tightly to IL-36R compared to the agonists, which has implications for understanding how to inhibit this pathway.
View Article and Find Full Text PDF